Keyt Bruce's Form 4 filing
IGM Biosciences, Inc. (IGMS) · filed May 25, 2023
- Accession no.
- 0001209191-23-032303
- Filed
- May 25, 2023
- Trade date
- May 15-23, 2023
- Filing delay
- 10 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $12.1K. It was filed 10 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Keyt BruceCIK 0001787362 | Officer (Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 15, 2023 | Common Stock | AGrant or awardAcquired | +960 | $11.71 | +$11,241.6 | 139,040 | Direct | |
| May 23, 2023 | Common Stock | SSaleDisposed | −970 | $12.30F3 | −$11,931 | 138,070 | Direct | |
| May 23, 2023 | Common Stock | SSaleDisposed | −12 | $13.01F4 | −$156.12 | 138,058 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
This transaction was executed in multiple trades at prices ranging from $12.00 to $12.95. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $13.00 to $13.02. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.